Proceeds from the financing will be used to expand the company's discovery platform that maps human tissue regulatory T cell behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
Investors include Eli Lilly and Company (NYSE: LLY), SV Health, Johnson and Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
TRexBio also appointed Johnston Erwin as chief executive officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical officer, as part of the company's plan to accelerate growth.
Johnston, a seasoned industry veteran with experience in business development, venture investment, collaboration management, and clinical and regulatory development, joins TRexBio after a 36 year career with Lilly.
He most recently served as VP of Corporate Business Development leading Lilly's internal venture portfolio.
Dr. Trifan brings more than 20 years of medical research experience to TRexBio. Most recently he was the Chief Medical officer and VP of Development at Apexigen, a clinical stage biotech company focused on immuno-oncology.
Prior to Apexigen he held senior roles in clinical research at leading pharmaceutical companies including Bristol Myers Squibb and Johnson and Johnson, where he contributed to the development of multiple successful oncology drugs.
Dr. Trifan will lead the advancement of TRexBio's oncology programs into the clinic by the end of next year.
Erwin and Dr. Trifan are joined on the management team by chief scientific officer Melanie Kleinschek, DVM, Ph.D., who has led the development of TRexBio's unique 'deep biology' discovery platform.
The platform uses high-resolution profiling of human tissue, modern computational biology tools, a proprietary system to generate tissue-like Tregs and disease-relevant phenotypic assays to generate novel insights into human tissue biology.
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases.
TRexBio is headquartered in South San Francisco, California.
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment